A high dose of the investigational oral therapy mesdopetam led to a significant and clinically meaningful reduction in levodopa-induced dyskinesia — the uncontrolled, involuntary movements and muscle stiffness common in Parkinson’s disease patients undergoing treatment — in a Phase 2 study, according to an in-depth examination of trial…
Osteoporosis, a condition marked by fragile bones and very low bone mineral density (BMD), was associated with an increased risk of Parkinson’s disease in postmenopausal women, a new large-scale study in Korea found. In fact, “individuals with osteoporosis had a 1.40-fold higher HR [hazard ratio] … than those with…
Adhering to healthy plant-based dietary patterns was associated with a reduced risk of developing Parkinson’s disease, especially among older people, according to a large-scale U.K. study. A higher intake of vegetables, nuts, and tea in the regular diet is linked to the lowest Parkinson’s risk, data show. “These results…
Exposure to alpha-synuclein, a protein that accumulates in the brains of Parkinson’s disease patients, led to inflammation and damage to nerve cells in the gut of mice carrying a human gene associated with several autoimmune disorders, a new study showed. Alpha-synuclein-related autoimmunity also induced constipation — a gut-related…
Racial disparities exist in the use of deep brain stimulation among people with Parkinson’s disease, a real-world claims study concluded. Compared to the proportion represented in the Medicare database, more people who identified as white, and fewer Black and Hispanic patients, underwent deep brain stimulation (DBS) for Parkinson’s.
Problems in quality control processes that support the health and function of mitochondria, crucial for cellular energy, are evident in nerve cells of people with Parkinson’s disease, a study showed. Mitochondrial recycling and protein balance were particularly impaired, which may impede energy production and lead to the early nerve…
NodThera’s NT-0796, an investigational oral therapy for Parkinson’s disease, reduced several inflammatory markers in elderly volunteers in seven days, according to initial data from a Phase Ib/IIa study. Parkinson’s patients are now being recruited for the trial’s second phase to determine the therapy’s impact on a panel of clinical…
A year of daily treatment with ursodeoxycholic acid (UDCA), a naturally occurring bile acid, led to small but significant improvements in motor abilities in adults with early Parkinson’s disease, a small Phase 2 study suggests. UDCA, already approved to treat a bile duct condition, also improved the function of…
The Rit2 protein clears toxic forms of the alpha-synuclein protein from nerve cells, where it manifests as a hallmark symptom of Parkinson’s disease, a study reveals. Targeting Rit2 could represent an effective strategy to combat nerve cell loss in familial and sporadic forms of the disease, its researchers noted.
A highly sensitive blood test accurately identified people with synucleinopathies, disorders caused by the abnormal aggregation of the protein alpha-synuclein, such as Parkinson’s disease. The test, called immunoprecipitation-based real-time quaking-induced conversion (IP/RT-QuIC), detected early-formed alpha-synuclein fibrils — or seeds — that eventually grew into disease-causing aggregates. Microscopic analysis detected…
Get regular updates to your inbox.
